Read by QxMD icon Read

Short course radiotherapy

P Han, F Y Liang, R H Chen, Q Cai, S T Yu, M R Luo, Y J Su, J Y Wang, X M Huang
Objective: Surgery is one of the salvage treatments for recurrent nasopharyngeal carcinoma. The safety and efficacy of Da Vinci's robotic surgery was preliminarily investigated to resect recurrent nasopharyngeal cancer after one-course radiotherapy. Method: Since Oct 2017, Da Vinci surgery system was used to complete the operation of locally recurrent nasopharyngeal carcinoma including two approaches, such as trans oral with soft palate incision and trans oral and nose with soft palate suspended. Result: Ten patients underwent robotic nasopharyngectomy, The median operation time was 90 minutes, median follow-up time was 6 months, and all patients had clear resection margins...
July 2018: Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery
Yuhong Dai, Hong Qiu
Malignant acute abdomen is a emergency with abrupt onset, rapid progress and often a complex etiology, presenting difficulties for treatment and high mortality. Therefore, multidisciplinary team (MDT) treatment modality is required. Compared with single-discipline diagnosis and treatment modality, diagnosis made from MDT discussion is more accurate, where specialists can improve efficiency and quality of the treatment through better communication. A good MDT can cover all stages from the diagnosis to the assessment and treatment of the disease, and combine them into a more coherent process...
November 25, 2018: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
Luca Bertamini, Jacopo Nanni, Giovanni Marconi, Mariachiara Abbenante, Valentina Robustelli, Francesco Bacci, Antonella Matti, Stefania Paolini, Chiara Sartor, Silvia Lo Monaco, Maria Chiara Fontana, Stefano De Polo, Michele Cavo, Antonio Curti, Giovanni Martinelli, Cristina Papayannidis
BACKGROUND: Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin. CASE PRESENTATION: We report two cases of CD22 positive relapsed EM-ALL treated with IO, obtained as compassionate use...
November 15, 2018: BMC Cancer
Neil Chevli, Gary D Lewis, Todd A Swanson
CONTEXT: Patients with locoregional anal carcinoma who don't qualify for standard definitive chemoradiation are candidates for a short course of palliative hypofractionated radiotherapy such as QUAD Shot. METHODS: A 57-year-old man with massive locoregional squamous cell carcinoma of the anal canal was treated with QUAD Shot (14.8 Gy in 4 fractions over 2 consecutive days) repeated every 4 weeks for a total of 2 courses. RESULTS: He reported symptomatic relief following each course of radiation...
November 4, 2018: Journal of Pain and Symptom Management
K-S Jeng, C-C Huang, C-S Chung, C-K Lin, C-J Teng, P-W Shueng, K-H Chen
The effective treatment for hepatocellular carcinoma (HCC) with American Joint Committee on Cancer stage IIIB remains controversial and challenging because of the high recurrence rate after resection and low survival rate. The median survival of those with macroscopic portal vein tumor thrombus (PVTT) is short. We reported such a case which received liver transplantation (LT) after successful consecutive downstaging therapies. A 40-year-old man with alcohol related liver cirrhosis and repeated esophageal varices bleeding had HCC with tumor thrombi in right main portal vein and the second portal branch of segment VI (stage IIIB)...
November 2018: Transplantation Proceedings
Ti-Hao Wang, Chia-Jen Liu, Tze-Fan Chao, Tzeng-Ji Chen, Yu-Wen Hu
AIM: To investigate second primary malignancy (SPM) risk after radiotherapy in rectal cancer survivors. METHODS: We used Taiwan's National Health Insurance Research Database to identify rectal cancer patients between 1996 and 2011. Surgery-alone, preoperative short course, preoperative long course, and post-operative radiotherapy groups were defined. The overall and site-specific SPM incidence rates were compared among the radiotherapy groups by multivariate Cox regression, taking chemotherapy and comorbidities into account...
October 28, 2018: World Journal of Gastroenterology: WJG
Ichiro Onishi, Masato Kayahara, Ryohei Takei, Naoki Makita, Masayoshi Munemoto, Yasumichi Yagi, Atsuhiro Kawashima
BACKGROUND: Most colorectal cancer liver metastases form nodules within the hepatic parenchyma, and hepatectomy is the only radical treatment for synchronous metastases. There is concern about intrabiliary tumor growth which may affect the surgical margin, resulting in local recurrence after hepatectomy for colorectal cancer liver metastasis; however, there has been no report of the dissemination in the bile duct after hepatectomy. Here, we report an unusual case of biliary dissemination of colorectal cancer that caused recurrent intrabiliary growth after hepatectomy, and discuss the management of intrabiliary metastasis of colorectal cancer...
October 27, 2018: Journal of Medical Case Reports
Roberta Fusco, Mario Sansone, Vincenza Granata, Robert Grimm, Ugo Pace, Paolo Delrio, Fabiana Tatangelo, Gerardo Botti, Antonio Avallone, Biagio Pecori, Antonella Petrillo
PURPOSE: To assess preoperative short-course radiotherapy (SCR) tumor response in locally advanced rectal cancer (LARC) by means of Standardized Index of Shape (SIS) by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), apparent diffusion coefficient (ADC), intravoxel incoherent motion (IVIM) and diffusion kurtosis imaging (DKI) parameters derived from diffusion-weighted MRI (DW-MRI). MATERIALS AND METHODS: Thirty-four patients with LARC who underwent MRI scans before and after SCR followed by delayed surgery, retrospectively, were enrolled...
October 25, 2018: Abdominal Radiology
J Livergant, M Howard, J Klein
AIMS: Palliative radiotherapy (PRT) can relieve symptoms and improve quality of life, but remains underutilised, possibly due to lack of referrals. We conducted a systematic review to study barriers impeding referral for PRT. MATERIALS AND METHODS: We searched EMBASE and MEDLINE to identify published studies of physician barriers to PRT referral. Data were synthesised using the percentage of respondents to the surveys in these studies who identified a given factor as a significant barrier to PRT referral...
October 20, 2018: Clinical Oncology: a Journal of the Royal College of Radiologists
Victoria Sopik, Ping Sun, Steven A Narod
BACKGROUND: After experiencing a distant recurrence, breast cancer patients have a poor prognosis; fewer than 5% survive for ten or more years. However, the time to death is highly variable, ranging from a few months to many years. The purpose of this study is to identify, in a large hospital-based series of patients with early-stage breast cancer, factors which predict survival after distant recurrence. METHODS: We studied a cohort of 2312 women diagnosed with invasive breast cancer at Women's College Hospital between 1987 and 2000 (stages I-III)...
October 16, 2018: Breast Cancer Research and Treatment
Eleonora Farina, Gabriella Macchia, Milly Buwenge, Giambattista Siepe, Alice Zamagni, Silvia Cammelli, Savino Cilla, Tigeneh Wondemagegnhu, Aynalem A Woldemariam, A F M Kamal Uddin, Mostafà Aziz Sumon, Francesco Cellini, Francesco Deodato, Alessio G Morganti
The main clinical goal for patients with advanced or metastatic thoracic cancer is palliation of tumor-related symptoms and improvement of quality of life. The aim of this phase I-II trial was to define the maximum tolerated dose (MTD) of a short-course of palliative radiotherapy (RT) and to evaluate its efficacy in terms of palliative response. A phase I trial was planned with escalating dose increments. Total doses ranged from 16 to 20 Gy delivered (BID) in two consecutive days. Dose limiting toxicity was defined as any acute grade ≥ 3 toxicity based on the RTOG scale...
December 2018: Clinical & Experimental Metastasis
Anna Gasinska, Beata Biesaga, Anna Janecka Widla, Zbigniew Darasz
BACKGROUND/AIMS: This is a retrospective analysis of 103 patients having locally advanced rectal cancer who received short-course radiotherapy (SCRT). The objective of the study was to check whether a polymorphism in the RAD51 gene (135 G>C), Ku70 protein expression, and tumor microenvironment: proliferation rate measured by BrdUrdLI and Ki-67LI, hypoxia (glucose transporter-1 expression), P53 protein expression, and DNA ploidy can influence DNA repair capacity, the factors contributing to patient overall survival (OS) and the incidence of recurrences and metastases...
October 5, 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
Yongjun Yu, Yuwei Li, Chen Xu, Zhao Zhang, Xipeng Zhang
BACKGROUND: rectal cancer (RC) is one of the most prevalent malignancies worldwide and different preoperative radiotherapies may lead to different outcomes. This meta-analysis aimed to compare the effectiveness of long-course (LC) and short-course radiotherapy (SC), with or without chemotherapy, for locally advanced rectal cancer. METHODS: studies published up to March 31st 2018 were retrieved from PubMed, Medline, Cochrane and EMABSE. Randomized control or consort control trials that reported the outcomes of short or long course radiotherapy were eligible...
October 4, 2018: Revista Española de Enfermedades Digestivas
Iosief Abraha, Cynthia Aristei, Isabella Palumbo, Marco Lupattelli, Stefano Trastulli, Roberto Cirocchi, Rita De Florio, Vincenzo Valentini
BACKGROUND: This is an update of the original review published in 2007.Carcinoma of the rectum is a common malignancy, especially in high income countries. Local recurrence may occur after surgery alone. Preoperative radiotherapy (PRT) has the potential to reduce the risk of local recurrence and improve outcomes in rectal cancer. OBJECTIVES: To determine the effect of preoperative radiotherapy for people with localised resectable rectal cancer compared to surgery alone...
October 3, 2018: Cochrane Database of Systematic Reviews
Anne Berberich, Tobias Kessler, Carina M Thomé, Stefan Pusch, Thomas Hielscher, Felix Sahm, Iris Oezen, Lara-Marie Schmitt, Sara Ciprut, Nanina Hucke, Petra Rübmann, Manuel Fischer, Dieter Lemke, Michael O Breckwoldt, Andreas von Deimling, Martin Bendszus, Michael Platten, Wolfgang Wick
PURPOSE: Resistance is an obstacle of glioma therapy. Despite targeted interventions, tumors harbor primary resistance or become resistant over short course of treatment. This study examined the mouse double minute 2 (MDM2) inhibitor RG7388 together with radiotherapy and analyzed strategies to overcome acquired MDM2 inhibitor resistance in glioblastoma. EXPERIMENTAL DESIGN: Effects of RG7388 and radiotherapy were analyzed in p53 wild-type glioblastoma cell lines and glioma-initiating cells...
October 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
R Glynne-Jones, M R Hall, A Lopes, S Pearce, V Goh, S Bosompem, J Bridgewater, I Chau, H Wasan, B Moran, L Melcher, N P West, P Quirke, W-L Wong, S Beare, N Hava, M Duggan, M Harrison
Background: Chemoradiation (CRT) or short-course radiotherapy (SCRT) are standard treatments for locally advanced rectal cancer (LARC). We evaluated the efficacy/safety of two neoadjuvant chemotherapy (NACT) regimens as an alternative prior to total mesorectal excision (TME). Methods/design: This multi-centre, phase II trial in patients with magnetic resonance imaging (MRI) defined high-risk LARC (>cT3b, cN2+ or extramural venous invasion) randomised patients (1:1) to FOLFOX + Bevacizumab (Arm 1) or FOLFOXIRI + bevacizumab (Arm 2) every 14 days for 6 cycles prior to surgery...
September 2018: Heliyon
Bin Ma, Peng Gao, Yongxi Song, Xuanzhang Huang, Hongchi Wang, Qingzhou Xu, Shan Zhao, Zhenning Wang
BACKGROUND: To assess whether preoperative short-course radiotherapy (PSRT) could be the treatment of choice compared to preoperative long-course chemoradiotherapy (PLCRT) METHODS: The PubMed, Embase, and Web of Science Databases were searched to conduct a systematic review and meta-analysis. Perioperative and survival outcomes between PSRT and PLCRT were selected as end points for our meta-analysis. In addition, health-related quality-of-life outcomes were also systematically reviewed between PSRT and PLCRT...
August 11, 2018: Clinical Colorectal Cancer
Kei Shibuya, Tatsuya Ohno, Kazuki Terashima, Shingo Toyama, Shigeo Yasuda, Hiroshi Tsuji, Tomoaki Okimoto, Yoshiyuki Shioyama, Kenji Nemoto, Tadashi Kamada, Takashi Nakano
BACKGROUND & AIMS: Carbon-ion radiation therapy has shown encouraging results in hepatocellular carcinoma patients in single-centre studies. We evaluated the effectiveness and safety of short-course carbon-ion radiation therapy for hepatocellular carcinoma in a multicentre study conducted by the Japan Carbon Ion Radiation Oncology Study Group. METHODS: Consecutive hepatocellular carcinoma patients who were treated with carbon-ion radiation therapy in four or fewer fractions at four Japanese institutions between April 2005 and November 2014 were analysed retrospectively...
September 21, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Savino Cilla, Francesco Deodato, Anna Ianiro, Gabriella Macchia, Vincenzo Picardi, Milly Buwenge, Silvia Cammelli, Alice Zamagni, Vincenzo Valentini, Alessio G Morganti
PURPOSE: This study aimed to assess the feasibility to plan and deliver highly heterogeneous doses to symptomatic large tumors using volumetric modulated arc therapy (VMAT) and simultaneous integrated boost (SIB) during a short course palliative accelerated radiotherapy. METHODS: A patient with a large symptomatic chordoma infiltrating the right gluteal region was selected. A modified SIB treatment was implemented to irradiate the central volume of the tumor (boost target volume, BTV) up to 10 Gy/fraction in a dose escalation trial while maintaining the remaining tumor volume (planning target volume, PTV) and the surrounding healthy tissues within 5 Gy/fraction in twice daily fractions for two consecutive days...
November 2018: Journal of Applied Clinical Medical Physics
Marco C Merlano, Anna M Merlotti, Lisa Licitra, Nerina Denaro, Elena Fea, Danilo Galizia, Massimo Di Maio, Claudia Fruttero, Paola Curcio, Stefania Vecchio, Elvio G Russi, Renzo Corvò
Introduction and background: Second-line treatment of platinum-resistant relapsed/metastatic (R/M) head and neck cancer (HNC) is a currently unmet clinical need. Clinical trials showed improvement in overall survival and quality of life of R/M-HNC patients treated with anti-PD-1 regardless of the number of prior chemotherapy lines; however, the percentage of long-term survivors remains limited.This study aims to test the hypothesis that attacking the tumor microenvironment at multiple levels can increase immunogenicity of R/M-HNC without worsening the safety profile of immune checkpoint inhibitors...
August 2018: Clinical and Translational Radiation Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"